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Abstract  
 
Combination of chemotherapeutic agent and chemopreventive agent is being a new 
approach in cancer treatment. This is aimed at enhancing the effectivity and also reducing drug 
resistance and adverse side effect of the chemotherapeutic agent. Hesperidin, a citrus flavonoid 
has reported to reduce the proliferation of many cancer cells. The objectives of this study were 
to investigate cytotoxic activities, cell cycle modulation and apoptosis induction of hesperidin 
and its combination with doxorubicin on Hela cell lines. MTT [3-(4,5-dimethylthiazol-2-yl)-2.5-
diphenyltetrazolium bromide] assay was used to measure the growth inhibitory effect of 
hesperidin and its combination with doxorubicin on Hela cells. Cell cycle profile was 
determined by flowcytometry and the data obtained was analyzed by using ModFit LT 3.0 
program. Apoptosis assay was done using double staining method using ethidium-bromide and 
acridine-orange. Hesperidin inhibited cell growth with IC50 48 μM, while the IC50 of doxorubicin 
was 1000 nM. Combination of 500 nM doxorubicin and 6 μM hesperidin showed strongest 
inhibitory effect toward Hela cells. Hesperidin of 24 µM accumulated HeLa cells at G1 phase, 
but its combination with 500 nM Doxorubicin gave G1 and S phase accumulation at 24 h 
incubation. Both of Hesperidin and Doxorubicin were capable of inducing apoptosis. In 
accordance of the apoptotic effect, hesperidin, doxorubicin and their combination decreased 
the expression Bcl-2 and increased the expression of Bax. According to this result, hesperidin 
has a potency to be developed as co-chemotherapeutic agent for cervical cancer. 
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INTRODUCTION 
 
Increasing the efficacy of chemotherapeutic 
agent could be achieved by combination with 
chemopreventive agent so that the effect will be 
better than it single treatment. Hesperidin, a citrus 
bioflavonoid showed strong toxic effect in Caco-2, 
CEM/ADR5000 and CCRF-CEM cancer cell lines 
with dengan IC 50 195, 230 dan 95 µM 
respectively (El-Readi et al., 2009). Hesperidin 
also showed antiproliferative effect in MCF-7 cells 
transfected with green fluoresens protein 
(GFP)/alpha-tubulin (MCF-7-GFP-Tubulin) (Lee 
et al., 2009). It is also reported that hesperidin 
protective effect in  benzo[a]pirene induced 
testicular toxicity paradigm and repaired the 
function of lactate dehydrogenase (LDH-X), 
superoxide dismutase (SOD), dan glutathione-S-
transferase (GST) enzyme (Arafa et al., 2009). 
Previous study has reported that Hesperidin could 
induce apoptosis in human colon cancer cells 
through CASP3 activation. Hesperidin down-
regulated the protein expression of pro-CASP3, 
and upregulated the level of active CASP3 (Park et 
al, 2008). 
It is suggested, based on above studies, 
that Hesperidin has a potency to be combined 
with chemotherapeutic agent (cochemotherapy) in 
treating human cancer cells. Worldwide, cervical 
cancer is the 5
th
 most common cancer in women 
with approximately 471,000 new cases diagnosed 
each year. The Caribbean, other parts of Africa, 
South America and South Eastern Asia have very 
high incidences of this disease (CC, 2010). Cancer 
therapy is usually done with chemotherapeutic 
agents, but they have many side effect and 
resistance.  
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One of them is doxorubicin. Cardiotoxicity is a 
well-known side effect of doxorubicin and is 
frequently a dose-limiting factor. The reduction in 
dose limiting side effects, therefore, represents a 
major challenge in improving the clinical 
application of these agents. This research is aimed 
to assess whether combination of Hesperidin with 
Doxorubicin (as model of chemotherapeutic agent) 
have synergistic effect and induce apoptosis on 
human cervical cancer Hela cells. 
 
MATERIALS AND METHODS 
 
Cell culture 
Cervical carcinoma cell line (HeLa) were 
obtained from Cancer Chemoprevention Research 
Centre, Faculty of Pharmacy, Gadjah Mada 
University.  Cell lines were grown in Dulbecco's 
modified Eagles medium (DMEM) with 10% 
Fetal Bovine Serum (Gibco) and 1% Penicillin-
Streptomycin (Gibco) at 37°C in a humidified 
atmosphere of 5% CO2/95% air.  
 
Cytotoxicity assay 
Cytotoxicity experiments were performed 
using MTT assay. Hela Cells were seeded at a 
density of 5x10
3
 cells/well and allowed to attach for 
24 h. One day after initial seeding, cells were treated 
with either various concentrations of Hesperidin 
(Sigma) alone Doxorubicin (Ebewe) alone and their 
combination. After 24h culture medium was 
removed and cells were washed in PBS 
(Sigma). Then, cells were incubated with 100 
µL culture medium and 10 µL MTT (Sigma) 5 
mg/mL in each well for 4-6 h. Stopper reagent 
was added after formazan formation prior to MTT 
reduction. The absorbance of each well was 
measured using ELISA reader at 595 nm (Bio-
Rad). The IC50 was determined using Excell MS 
Office 2007 and probit analysis (SPSS 11.5).  
 
Apoptosis Detection 
Apoptosis was detected using acrydine 
orange-ethidium bromide staining (AO/EB double 
staining). Hela cells (5 x 10
4
 cells/well) were 
seeded on coverslips in 24-well plates until 50-60% 
confluent. Cells were then incubated with 
Hesperidin alone, Doxorubicin alone and their 
combination for 24 h. Culture medium was 
removed and cells were washed with PBS. 
Coverslips were placed into object-glass and 
added with 10 µL 1X working solution 
acrydine orange (Sigma) - ethidium bromide 
(Sigma), observed using fluoroscence microscopy 
(Zeiss MC 80). Apoptotic cells which had lost 
their membrane integrity appeared orange and 
showed morphological features of apoptosis. Cells 
were identified as apoptotic on the basis of specific 
morphological criteria, including condensation and 
fragmentation of chromatin, and formation of 
apoptotic bodies. 
 
Cell Cycle Analysis 
Hela cells were seeded at 5 x 10
5
 cells/well 
on six wells tissue culture plate.  After 24 hours 
incubation cells were treated with Hesperidin (12 
µM or 24 µM) alone or its combination with 
doxorubicin (500 nM). After 24 h of these 
treatments, cells were trypsinized and cells pellets 
were collected. Cells were trypsinized, spin at 2000 
rpm for 3 minutes and washed twice with cold 
PBS. Cells were resuspended in propidium iodide 
solution (50 µg/ml in PBS contained 1% triton X-
100) and then treated with RNAse DNAse free (20 
µg/ml) for 10 minutes at 37
0
C. The treated cells 
then subjected to FACS flowcytometry and data 
was analyzed by using ModFit LT 3.0 program. 
 
Immunocytochemistry 
Cells were plated at 5 X 10
4
 cells/well and 
cultured in 24-wells plate at cover slip until 80 % 
confluent. At time 0, medium was replaced by 
fresh complete medium with hesperidin 24 µM and 
doxorubicin 500 nM and incubated in CO-2 5% 
incubator at 37
o
C for 18 hours. Then, cells were 
harvested and were washed with PBS and fixed 
with cold methanol for 10 min at freezer -4
0
C. 
Cells washed, and blocked in hydrogen peroxide 
blocking solution for 10 minutes at room 
temperature. After that, cells washed with PBS and 
incubated with prediluted blocking serum for 10 
minutes at room temperature. Cells were stained 
for 1 h at room temperature with primary Ab (Bcl-
2 and Bax). After washing three times in PBS, 
secondary antibody were applied for 15-30 min, 1: 
2 in PBS and added 5% AB serum then washed 
with PBS three times. The slide was incubated with 
streptavidin-biotin-complex for 15 min, 1 : 2 in 
PBS and added 5% AB serum and washed three 
times in PBS. Slides were incubated in DAB (3,3 
diaminobenzidin) solution for 3-8 min and washed 
with aquadest. Cells were counterstained for 3-4 
min with Mayer-Haematoksilin. After incubation, 
coverslip washed with aquadest and then immersed 
with xylol and alcohol. Protein expression was 
assessed under light microscope. Positive 
expression will give a dark brown colour in 
nucleus and cells with no expreesion will give 
purple. 
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RESULTS AND DISCUSSION 
 
Effect of Hesperidin and Doxorubicin on cell 
growth 
Cell viability assay was done to determine 
the inhibitory concentration (IC50) of Hesperidin 
alone, Doxorubicin alone and their combination on 
Hela cells. All of these compounds showed growth 
inhibitory effect in dose dependent manner. 
Hesperidin and Doxorubicin had the IC50 values of 
48 µM and 1 µM, respectively. Combination of 
Hesperidin and Doxorubicin decreased viability 
cells more than Doxorubicin alone (Fig.1). The 
lowest viability (58,05%) showed by combination 
of 24 µM Hesperidin, and 500 nM Doxorubicin. 
 
Figure 1. Cell viability assay of (A) Hesperidin, (B) Doxorubicin (C) Combination of Hesperidin and 
Doxorubicin in Hela cells. Result showed that Hesperidin and Doxorubicin had the IC50 values of 48 
µM and 1000 nM, respectively. Every dot is means from 3 replication. Cells photo 100x 
magnification.           viable cells,            cells with morphological changes. 
 
 
Effect of Hesperidin and Doxorubicin on 
apoptosis  
Both of Hesperidin and Doxorubicin were 
capable of inducing apoptosis at inhibitory 
concentration (Fig. 2). The green fluorescence 
indicates the viable cells while the orange-red 
fluorescence indicates the death cells. Apoptotic 
cells show the occurrence of chromatin 
condensation and the orange-red apoptotic bodies. 
Combination of Hesperidin and Doxorubicin 
appeared to have the strongest apoptotic effect. 
 
 
 
 
 
 
Kusharyanti, et al., 2011 
Indones. J. Cancer Chemoprevent., 2(2), 267-273 
 
270 
 
 
 
 
 
 
 
Figure 2. Apoptosis induction of Hesperidin and Doxorubicin in Hela cells. (A) control cells, (B), (C), and 
(D) cell treated with 24 µM Hesperidin, 500 nM Doxorubicin, and combination of 24 µM 
Hesperidin- 500 nM Doxorubicin at incubation time 24 h. Cells was stained with  acrydine orange-
ethidium bromide and saw in fluorosence microscope. 100x magnification.              apoptosis,  
                          viable cells 
 
Effect Hesperidin and Doxorubicin on cell 
cycle progression of cancer cell 
Flowcytometric analysis was used to 
observed the distribution of cell population on cell 
cycle. As shown in Fig. 3, there was an 
accumulation at G1 phase of Hela cells treated 
with 24 µM Hesperidin. But treatment with 500 
nM Doxorubicin, and combination of 24 µM 
Hesperidin- 500 nM Doxorubicin showed 
accumulation at S phase at incubation time 24 h.  
.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Flowcytometric analysis. Cells were treated with 24 µM Hesperidin, 500 nM Doxorubicin, and 
combination of 24 µM Hesperidin- 500 nM Doxorubicin at incubation time 24 h, and stained with 
propidium iodide.  
 
Effect Hesperidin and Doxorubicin on Bcl-2 
and Bax Expression on HeLa cell lines 
To confirm the mechanism of hesperidin 
and its combination with doxorubicin induced 
apoptosis, this research observed the effect of 
hesperidin, doxorubicin and their combination on 
the expression of Bax, and Bcl-2 by using 
immunocytochemistry method. Interestingly, the 
expression of Bcl-2 on the hesperidin and 
doxorubicin treated cells was decreased compare to 
the control cells but the decreasing level of Bcl-2 
expression on the combination treated cells was 
higher than on the hesperidin and doxorubicin 
single treated cells (Fig. 4). Moreover, the 
increasing level of Bax expression on the both 
single and combination treated cells not 
significantly different, but still higher than the 
control cells (Fig. 4). These data show that the 
combination more potent to induce apoptosis on 
the HeLa cells than single treatment. 
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Fig 4. Protein involves in apoptotic process on HeLa cells examined by immunocytochemistry methods (A) 
Control cells without antibody (B) Control cells with Bcl-2 Ab (C) Doxorubicin 500nM with Bcl-2 Ab 
(D) Hesperidin 24 µM with Bcl-2 Ab (E) Doxorubicin 500nM-Hesperidin 24 µM with Bcl-2 Ab (F) 
Control cells with Bax Ab (G) Doxorubicin 500nM with Bax Ab (H) Hesperidin 24 µM with Bax Ab (I) 
Doxorubicin 500nM-Hesperidin 24 µM with Bax Ab. This experiment used DAB as the chromogen, 
dark brown staining in nucleus indicated the positive expression (       ), cells were counterstained 
with H&E showed purple color indicated negative expression (          ) of the protein. 
 
The results of this study demonstrate the 
ability of hesperidin as an anti-cancer which has 
the potency of inhibiting cell proliferation. 
Cytotoxic properties can be associated with the 
ability to spur occurrence of cell cycle arrest or 
accelerate apoptosis in cells. Our data found that 
hesperidin induce cell cycle arrest in G1 phase. But 
when hesperidin combined with doxorubicin, its 
induced both cell cycle arrest in G1 and S phase. 
So maybe doxorubicin and hesperidin have 
different mechanism that cause cell cycle arrest 
and this bring a synergistic effect. The occurrence 
of cell cycle arrest may be through different 
mechanisms involving various proteins. Protein 
p21 and p27 is a member of Cip / Kip proteins can 
form a trimer with cyc D-CDK complexes 
(holoenzim). Trimer with holoenzim will result 
holoenzim can not phosphorylate pRB, so the cells 
will arrest in G1. Protein p53 is regulator that can 
stimulate expression of p21, which can cause cell 
cycle arrest in G1 phase (Andrei, 2002). In HeLa 
cells, p53 protein was already degraded by E6 is 
expressed by the HVP. So that maybe hesperidin 
can stabilized or even increase p53 levels.  
This present study showed that hesperidin, 
doxorubicin and their combination induced 
apoptosis in HeLa. Apoptosis can occur through 
various mechanisms. NF-κB proteins can inhibit 
apoptosis through increased transcription of Bcl-2 
that works to prevent the release of cytochrome c 
in mitochondria by Bax (Simstein et al., 2003). 
The inhibition of NF-kB also causes decreasing of 
Bcl-2 and Bcl-xL expression, two main 
antiapoptotic proteins. Hesperidin inhibit Bcl-2 
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expression in colon cancer cells (Park et al., 2008). 
Hesperidin and doxorubicin show decreasing of 
Bcl-2 level on HeLa. Hesperidin suppressed TPA-
stimulated NF-κB translocation into the nucleus 
through IκB inhibitory signaling pathways and also 
inhibited TPA-induced AP-1 activity by the 
inhibitory phosphorylation of p38 kinase and c-Jun 
N-terminal kinase (JNK) signaling pathways (Lee 
et al, 2010) and inhibition of PI3K path that 
eventually spur apoptosis through inhibition of 
inactivation of Bad (Gu et al., 2004). Increased 
apoptosis by the combination of hesperidin and 
doxorubicin via inhibition of NF-κB activation can 
also occur through inhibition of MAP kinase and 
PI3K path.  
The result of this present study showed 
increasing Bax level significantly due to 
hesperidin, doxorubicin and their combination 
induction. These data suggested that the apoptosis 
may occur by increasing Bax level. Desaintes et 
al., (1999) proved that, increase of p53 in HeLa 
cells increases the expression of p21 but not 
increased expression of Bax. The possibility of 
apoptosis occurred due to intervention with another 
pathway beside p53 induction as one of Bax 
activator. Joubert et al., (2005) reported that there 
was increasing level of Bax and decreasing level of 
Bcl-2 in Hela due to prostaglandin A2 and 2-
methoxyestradiol treatment. Eventhough Bax 
expression level was positively regulate by p53, 
but Bax level remain increasing on p53 mutant cell 
line like T47D (Butt et al., 2000). So this is 
indicating that hesperidin could interfere another 
pathway to increase Bax level. Activation of 
caspase 8 by formation of DISC activates the 
downstream caspases through the cleavage of Bid 
into tBid. This could induce oligomerization of 
Bax and couse apoptosis (Rastogi et al., 2009). But 
to prove this suggestion still needed more 
investigation.  
Overall hesperidin can increase the 
effectiveness of doxorubicin. Despite this need to 
conduct further research to explore the potential of 
doxorubicin combined with hesperidin, especially 
the molecular mechanisms that facilitate increased 
effect of  doxorubicin.  In addition, a combination 
of in vivo testing is needed in order to develop 
hesperidin as an cochemotherapy agent. 
 
CONCLUSION 
  
Hesperidin has cytotoxic effect on Hela cells 
with IC50 48 µM. Co-chemotherapy application of 
doxorubicin -hesperidin on Hela cells showed 
synergism effect through cell cycle modulation and 
apoptosis induction. 
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